Home > Resources > Whitepapers > Pharmaceutical policy in China

Pharmaceutical policy in China

Pharmaceuticals make a significant contribution to the health and well-being of a population and government policy regarding pharmaceuticals exerts a significant effect on the state of the pharmaceutical market. Governments generally have several objectives when developing pharmaceutical policy. For example, the World Health Organization (WHO) suggests that a national pharmaceutical policy should adhere to three key principles (WHO, 2001).

Spotlight

Promoveo Health

Promoveo Health is a contract sales and marketing solutions company that does most of its work in the pharmaceutical, dental and medical device industries. We are also called a contract sales company but don't let the word "contract" lead you to believe that the representatives are 1099 as they are not - all of the representatives that work for Promoveo Health are W2 employees.

OTHER WHITEPAPERS

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

The Ultimate Guide to Pharmaceutical Quality Managemen

whitePaper | October 20, 2022

When the first Nokia and Motorola cell phones that were affordable and small enough to fit in your pocket hit the market, they not only changed how we viewed phone technology but how we communicated.

Understanding the true cost of transparency reporting

whitePaper | December 14, 2022

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, it introduced new complexities for these businesses.

The Next Generation of Rare Disease Drug Policy

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

Advancing drug development using in silico modeling

whitePaper | June 22, 2022

The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.